RBC Capital Reiterates Sector Perform on IGM Biosciences, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has reiterated a 'Sector Perform' rating on IGM Biosciences (NASDAQ:IGMS) and maintained a price target of $11.
August 17, 2023 | 1:53 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital has reiterated a 'Sector Perform' rating on IGM Biosciences and maintained a price target of $11.
The reiteration of the 'Sector Perform' rating by RBC Capital indicates that they believe IGM Biosciences will perform in line with the expectations of the sector. The maintained price target of $11 suggests that they do not foresee any significant price movement in the short term. This could potentially lead to a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100